Identification of a mechanism for lung inflammation caused by Mycoplasma pneumoniae using a novel mouse model

Results in Immunology

Volumn 1, Issue 1, 2011, Pages 76-87

  Saraya, Takeshi ^a   Nakata, Koh ^b   Nakagaki, Kazuhide ^c   Motoi, Natsuki ^b   Iihara, Kuniko ^d   Fujioka, Yasunori ^a   Oka, Teruaki ^e   Kurai, Daisuke ^a   Wada, Hiroo ^a   Ishii, Haruyuki ^a   Taguchi, Haruhiko ^f   Kamiya, Shigeru ^a   Goto, Hajime ^a  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

^c Nippon Jui Seimeikagaku University   (Japan)

^d Nippon Telegraph and Telephone Corporation Medical Center Tokyo   (Japan)

^e Mutual Aid Association of Public School Teachers   (Japan)

^f KYORIN UNIVERSITY   (Japan)

Author keywords

Alveolar macrophage; Mice model; Mycoplasma pneumonia extracts; Mycoplasma pneumoniae pneumonia; Plasma cell; Toll like receptor 2

Indexed keywords

ALUMINUM POTASSIUM SULFATE; LIPOPROTEIN; MICROBIAL PRODUCTS NOT CLASSIFIED ELSEWHERE; MYCOPLASMA PNEUMONIAE EXTRACT; TOLL LIKE RECEPTOR 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGENICITY; ARTICLE; BACTERIAL CELL WALL; BACTERIAL STRAIN; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INNATE IMMUNITY; LUNG ALVEOLUS MACROPHAGE; MOUSE; MYCOPLASMA; MYCOPLASMA PNEUMONIA; MYCOPLASMA PNEUMONIAE; NONHUMAN; POSITIVE FEEDBACK; PRIORITY JOURNAL; RECEPTOR UPREGULATION; TH2 CELL;

EID: 81355147312     PISSN: None     EISSN: 22112839     Source Type: Journal    
DOI: 10.1016/j.rinim.2011.11.001     Document Type: Article

References (55)

1. Chan ED, Welsh CH. Fulminant Mycoplasma pneumoniae pneumonia. Western Journal of Medicine 1995; 162:133-42.
2. Rottem S. Interaction of mycoplasmas with host cells. Physiological Reviews 2003;83:417-32.
3. Dimitrov DS, Franzoso G, Salman M, Blumenthal R, Tarshis M, Barile MF, et al. Mycoplasma fermentans (incognitus strain) cells are able to fuse with T lymphocytes. Clinical Infectious Diseases 1993;17(Suppl. 1):S305-308.
4. Yano T, Ichikawa Y, Komatu S, Arai S, Oizumi K. Association of Mycoplasma pneumoniae antigen with initial onset of bronchial asthma. American Journal of Respiratory and Critical Care Medicine 1994;149:1348-53.
5. Dakhama A, Kraft M, Martin RJ, Gelfand EW. Induction of regulated upon activation, normal T cells expressed and secreted (RANTES) and transforming growth factor-beta 1 in airway epithelial cells by Mycoplasma pneumoniae. American Journal of Respiratory Cell and Molecular Biology 2003;29:344-51.
6. Benisch BM, Fayemi A, Gerber MA, Axelrod J. Mycoplasmal pneumonia in a patient with rheumatic heart disease. American Journal of Clinical Pathology 1972;58:343-8.
7. Halal F, Brochu P, Delage G, Lamarre A, Rivard G. Severe disseminated lung disease and bronchiectasis probably due to Mycoplasma pneumoniae. Canadian Medical Association Journal 1977;117:1055-6.
8. Kaufman JM, Cuvelier CA, Van der Straeten M. Mycoplasma pneumonia with fulminant evolution into diffuse interstitial fibrosis. Thorax 1980;35: 140-4.
9. Koletsky RJ, Weinstein AJ. Fulminant Mycoplasma pneumoniae infection. Report of a fatal case, and a review of the literature. American Review of Respiratory Disease 1980;122:491-6.
10. Maisel JC, Babbitt LH, John TJ. Fatal Mycoplasma pneumoniae infection with isolation of organisms from lung. Journal of the American Medical Association 1967;202:287-90.
11. Meyers BR, Hirschman SZ. Fatal infections associated with Mycoplasma pneumoniae: discussion of three cases with necropsy findings. Mount Sinai Journal of Medicine 1972;39:258-64.
12. Parker Jr F, Jolliffe LS, Finland M. Primary atypical pneumonia; report of eight cases with autopsies. Archives of Pathology (Chicago) 1947;44:581-608.
13. Coultas DB, Samet JM, Butler C. Bronchiolitis obliterans due to Mycoplasma pneumoniae. Western Journal of Medicine 1986;144:471-4.
14. Ebnother M, Schoenenberger RA, Perruchoud AP, Soler M, Gudat F, Dalquen P. Severe bronchiolitis in acute Mycoplasma pneumoniae infection. Virchows Archiv2001;439:818-22.
15. Llibre JM, Urban A, Garcia E, Carrasco MA, Murcia C. Bronchiolitis obliterans organizing pneumonia associated with acute Mycoplasma pneumoniae infection. Clinical Infectious Diseases 1997;25:1340-2.
16. Rollins S, Colby T, Clayton F. Open lung biopsy in Mycoplasma pneumoniae pneumonia. Archives of Pathology and Laboratory Medicine 1986;110:34-41.
17. Wachowski O, Demirakca S, Muller KM, Scheurlen W. Mycoplasma pneumoniae associated organising pneumonia in a 10 year old boy. Archives of Disease in Childhood 2003;88:270-2.
18. Chan ED, Kalayanamit T, Lynch DA, Tuder R, Arndt P, Winn R, et al. Mycoplasma pneumoniae-associated bronchiolitis causing severe restrictive lung disease in adults: report of three cases and literature review. Chest 1999;115:1188-94.
19. Ganick DJ, Wolf son J, Gilbert EF, Joo P. Mycoplasma infection in the immunosuppressed leukemic patient. Archives of Pathology and Laboratory Medicine 1980;104:535-6.
20. Nakajima M, Kubota Y, Miyashita N, Kishimoto T, Kobashi Y, Niki Y, et al. [An adult case of pneumonia due to Mycoplasma pneumoniae and Chlamydia psittaci]. Kansenshogaku Zasshi 1996;70:87-92.
21. Ohmichi M, Miyazaki M, Ohchi T, Morikawa Y, Tanaka S, Sasaki H, et al. [Fulminant Mycoplasma pneumoniae pneumonia resulting in respiratory failure and a prolonged pulmonary lesion]. Nihon Kokyuki Gakkai Zasshi 1998;36:374-80.
22. Bott L, Santos C, Thumerelle C, Mars A, Deschildre A, Catteau B. [Severe Stevens-Johnson syndrome in 4 children]. Archives of Pediatrics 2007;14: 1435-8.
23. Biberfeld G, Biberfeld P, Sterner G. Cell-mediated immune response following Mycoplasma pneumoniae infection in man. I. Lymphocyte stimulation. Clinical & Experimental Immunology 1974;17:29-41.
24. Mizutani H, Kitayama T, Hayakawa A, Nagayama E. Delayed hypersensitivity in mycoplasma pneumoniae infections. Lancet 1971;1:186-7.
25. Biberfeld G, Sterner G. Tuberculin anergy in patients with Mycoplasma pneumoniae infection. Scandinavian Journal of Infectious Diseases 1976;8:71-3.
26. Hardy RD, Jafri HS, Olsen K, Hatfield J, Iglehart J, Rogers BB, et al. Mycoplasma pneumoniae induces chronic respiratory infection, airway hyperreactivity, and pulmonary inflammation: a murine model of infection-associated chronic reactive airway disease. Infection and Immunity 2002;70:649-54.
27. Sutherland ER, Martin RJ. Asthma and atypical bacterial infection. Chest 2007;132:1962-6.
28. Underhill DM, Ozinsky A, Hajjar AM, Stevens A, Wilson CB, Bassetti M, et al. The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature 1999;401:811-5.
29. Shimizu T, Kida Y, Kuwano K. Mycoplasma pneumoniae-derived lipopeptides induce acute inflammatory responses in the lungs of mice. Infection and Immunity 2008;76:270-7.
30. Chu HW, Jeyaseelan S, Rino JG, Voelker DR, Wexler RB, Campbell K, et al. TLR2 signaling is critical for Mycoplasma pneumoniae-induced airway mucin expression. Journal of Immunology 2005;174:5713-9.
31. Hayakawa M, Taguchi H, Kamiya S, Fujioka Y, Watanabe H, Kawai S, et al. Animal model of Mycoplasma pneumoniae infection using germfree mice. Clinical and Diagnostic Laboratory Immunology 2002;9:669-76.
32. Sekine H, Taguchi H, Watanabe H, Kawai S, Fujioka Y, Goto H, et al. Immunological analysis and pathological examination of gnotobiotic mice monoassociated with Mycoplasma pneumoniae. Journal of Medical Microbiology 2009;58:697-705.
33. Chu HW, Breed R, Rino JG, Harbeck RJ, Sills MR, Martin RJ. Repeated respiratory Mycoplasma pneumoniae infections in mice: effect of host genetic background. Microbes and Infection 2006;8:1764-72.
34. O'Sullivan MG, Chilton FH, Huggins Jr EM, McCall CE. Lipopolysaccharide priming of alveolar macrophages for enhanced synthesis of prostanoids involves induction of a novel prostaglandin H synthase. Journal of Biological Chemistry 1992;267:14547-50.
35. Shimizu T, Kida Y, Kuwano K. A dipalmitoylated lipoprotein from Mycoplasma pneumoniae activates NF-kappaB through TLR1, TLR2, and TLR6. Journal of Immunology 2005;175:4641-6.
36. Chu HW, Campbell JA, Rino JG, Harbeck RJ, Martin RJ. Inhaled fluticasone propionate reduces concentration of Mycoplasma pneumoniae, inflammation, and bronchial hyperresponsiveness in lungs of mice. Journal of Infectious Diseases 2004;189:1119-27.
37. Fonseca-Aten M, Rios AM, Mejias A, Chavez-Bueno S, Katz K, Gomez AM, et al. Mycoplasma pneumoniae induces host-dependent pulmonary inflammation and airway obstruction in mice. American Journal of Respiratory Cell and Molecular Biology 2005;32:201-10.
38. Hardy RD, Jafri HS, Olsen K, Wordemann M, Hatfield J, Rogers BB, et al. Elevated cytokine and chemokine levels and prolonged pulmonary airflow resistance in a murine Mycoplasma pneumoniae pneumonia model: a micro-biologic, histologic, immunologic, and respiratory plethysmographic profile. Infection and Immunity 2001;69:3869-76.
39. Kurata S, Taguchi H, Sasaki T, Fujioka Y, Kamiya S. Antimicrobial and immunomodulatory effect of clarithromycin on macrolide-resistant Mycoplasma pneumoniae. Journal of Medical Microbiology 2010;59: 693-701.
40. Martin RJ, Chu HW, Honour JM, Harbeck RJ. Airway inflammation and bronchial hyperresponsiveness after Mycoplasma pneumoniae infection in a murine model. American Journal of Respiratory Cell and Molecular Biology 2001;24:577-82.
41. Opitz O, Pietsch K, Ehlers S, Jacobs E. Cytokine gene expression in immune mice reinfected with Mycoplasma pneumoniae: the role of T cell subsets in aggravating the inflammatory response. Immunobiology 1996;196:575-87.
42. Techasaensiri C, Tagliabue C, Cagle M, Iranpour P, Katz K, Kannan TR, et al. Variation in colonization, ADP-ribosylating and vacuolating cytotoxin, and pulmonary disease severity among Mycoplasma pneumoniae strains. American Journal of Respiratory and Critical Care Medicine 2010;182: 797-804.
43. Wubbel L, Jafri HS, Olsen K, Shelton S, Barton Rogers B, Gambill G, et al. Mycoplasma pneumoniae pneumonia in a mouse model. Journal of Infectious Diseases 1998;178:1526-9.
44. Barile MF, Chandler DK, Yoshida H, Grabowski MW, Razin S. Hamster challenge potency assay for evaluation of Mycoplasma pneumoniae vaccines. Infection and Immunity 1988;56:2450-7.
45. Cimolai N, Taylor GP, Mah D, Morrison BJ. Definition and application of a histopathological scoring scheme for an animal model of acute Mycoplasma pneumoniae pulmonary infection. Microbiology and Immunology 1992;36:465-78.
46. Dajani AS, Clyde Jr WA, Denny FW. Experimental Infection with Mycoplasma pneumoniae (Eaton's Agent). Journal of Experimental Medicine 1965; 121: 1071-1086.
47. Fernald GW, Clyde Jr WA, Bienenstock J. Immunoglobulin-containing cells in lungs of hamsters infected with Mycoplasma pneumoniae. Journal of Immunology 1972;108:1400-8.
48. Jacobs E, Drews M, Stuhlert A, Buttner C, Klein PJ, Kist M, et al. Immunological reaction of guinea-pigs following intranasal Mycoplasma pneumoniae infection and immunization with the 168 kDa adherence protein. Journal of General Microbiology 1988;134:473-9.
49. Shimizu T, Kida Y, Kuwano K. A triacylated lipoprotein from Mycoplasma genitalium activates NF-kappaB through Toll-like receptor 1 (TLR1) and TLR2. Infection and Immunity 2008;76:3672-8.
50. Kim JJ, Nottingham LK, Sin JI, Tsai A, Morrison L, Oh J, et al. [8CD] positive T cells influence antigen-specific immune responses through the expression of chemokines. Journal of Clinical Investigation 1998;102:1112-24.
51. Galkina E, Thatte J, Dabak V, Williams MB, Ley K, Braciale TJ. Preferential migration of effector CD8 + T cells into the interstitium of the normal lung. Journal of Clinical Investigation 2005;115:3473-83.
52. Stellato C, Beck LA, Gorgone GA, Proud D, Schall TJ, Ono SJ, et al. Expression of the chemokine RANTES by a human bronchial epithelial cell line. Modulation by cytokines and glucocorticoids. Journal of Immunology 1995;155:410-8.
53. Thaikoottathil JV, Martin RJ, Zdunek J, Weinberger A, Rino JG, Chu HW. Cigarette smoke extract reduces VEGF in primary human airway epithelial cells. European Respiratory Journal 2009;33:835-43.
54. McDonald DM. Angiogenesis and remodeling of airway vasculature in chronic inflammation. American Journal of Respiratory and Critical Care Medicine 2001;164:S39-45.
55. FanJ, Li Y, Vodovotz Y, BilliarTR, Wilson MA. Neutrophil NAD(P)H oxidase is required for hemorrhagic shock-enhanced TLR2 up-regulation in alveolar macrophages in response to LPS. Shock 2007;28:213-8.